Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
22 July 2021Website:
http://www.absci.comNext earnings report:
21 March 2025Last dividends:
N/ANext dividends:
N/APrice
after hours | Wed, 20 Nov 2024 00:56:41 GMTDividend
Analysts recommendations
Institutional Ownership
ABSI Latest News
Absci Corporation (NASDAQ:ABSI ) Q3 2024 Earnings Conference Call November 12, 2024 8:00 AM ET Company Participants Alex Khan - VP, Finance and IR Sean McClain - Founder and CEO Zach Jonasson - CFO and Chief Business Officer Christian Stegmann - SVP of Drug Creation Conference Call Participants Srikripa Devarakonda – Truist Securities Brendan Smith - TD Cowen George Farmer – Scotiabank Vamil Divan - Guggenheim Securities Operator Good day and thank you for standing by. Welcome to the Absci Q3 2024 Business Update Conference Call.
Successfully delivered AI de novo designed antibody sequences to AstraZeneca, fulfilling first milestone under collaboration
VANCOUVER, Wash. and NEW YORK, Oct. 15, 2024 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a data-first generative AI drug creation company, today announced the company will report business updates and financial and operating results for the third quarter before market open on Tuesday, November 12, 2024.
Absci Corporation's initiation of a phase 1 study using ABS-101 for the treatment of patients with IBD expected early 2025, with interim data to be released in the 2nd half of 2025. ABS-101 aims to differentiate itself with unique features like de novo antibody creation, multiparameter lead optimization, and reverse immunology, potentially offering superior potency and dosing flexibility. The global Crohn's Disease treatment market is expected to reach $17.80 billion by 2033.
VANCOUVER, Wash. and NEW YORK, Aug. 21, 2024 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a data-first generative AI drug creation company, today announced the company will be participating in the following upcoming investor conferences.
Absci Corporation (NASDAQ:ABSI ) Q2 2024 Earnings Conference Call August 14, 2024 4:30 PM ET Company Participants Alex Khan - VP, Finance and IR Sean McClain - Founder and CEO Zach Jonasson - CFO and Chief Business Officer Christian Stegmann - SVP of Drug Creation Conference Call Participants Steven Mah - TD Cowen Srikripa Devarakonda - Truist George Farmer - Scotiabank Scott Schoenhaus - KeyBanc Operator Good day and thank you for standing by. Welcome to the Absci Second Quarter 2024 Business Update Conference Call.
Absci Corporation (ABSI) came out with a quarterly loss of $0.22 per share versus the Zacks Consensus Estimate of a loss of $0.19. This compares to loss of $0.27 per share a year ago.
Absci Corporation Leverages AI For Rapid Drug Discovery And Promising Partnerships
VANCOUVER, Wash. and NEW YORK, July 03, 2024 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a data-first generative AI drug creation company, today announced that on July 1, 2024, the company granted a non-statutory stock option to purchase an aggregate of 613,000 shares of its common stock to Ms. Shelby Walker in connection with her employment as Absci's Chief Legal Officer. The inducement grant was previously approved by Absci's Board of Directors pursuant to Absci's 2023 Inducement Plan (the “Inducement Plan”), and is being made as an inducement material to Ms. Walker's acceptance of employment with the company in accordance with Nasdaq Listing Rule 5635(c)(4).
ABSCI Corporation's stock experienced a significant increase in the last trading session, accompanied by above-average trading volume. However, the recent changes in earnings estimates may not lead to additional price growth in the short term.
What type of business is Absci?
Absci Corporation operates as a data-first generative artificial intelligence (AI) drug creation company in the United States. The company combines AI with scalable wet lab technologies to create biologics for patients. Its integrated drug creation platform is designed to improve upon traditional biologic drug discovery by using AI to simultaneously optimize multiple drug characteristics that may be important to development and therapeutic benefit. It has a collaboration with Memorial Sloan Kettering Cancer Center to discover novel therapeutics using generative AI; with AstraZeneca PLC for AI-driven drug discovery against an oncology target; and with Twist Bioscience Corporation to design a novel therapeutic using generative AI. The company was founded in 2011 and is headquartered in Vancouver, Washington.
What sector is Absci in?
Absci is in the Healthcare sector
What industry is Absci in?
Absci is in the Biotechnology industry
What country is Absci from?
Absci is headquartered in United States
When did Absci go public?
Absci initial public offering (IPO) was on 22 July 2021
What is Absci website?
https://www.absci.com
Is Absci in the S&P 500?
No, Absci is not included in the S&P 500 index
Is Absci in the NASDAQ 100?
No, Absci is not included in the NASDAQ 100 index
Is Absci in the Dow Jones?
No, Absci is not included in the Dow Jones index
When was Absci the previous earnings report?
No data
When does Absci earnings report?
The next expected earnings date for Absci is 21 March 2025